Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 12,225 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Acne Vulgaris
Interventions: Trifarotene; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 9 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 9
States / cities: Fort Smith, Arkansas • Beverly, Massachusetts • Portsmouth, New Hampshire + 6 more

Conditions: Myeloma
Interventions: DS-3032b; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Metabolic Disease, Aneurysm, Neurologic Disorder
Interventions: MRI Scan; Diagnostic Test
Lead sponsor: Hercules; Industry
Eligibility: 18 Years and older
Enrollment: 100,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2037
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Respiratory Syncytial Virus Infection
Interventions: Sisunatovir, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 14
States / cities: Garden Grove, California • Westminster, California • Miami, Florida + 9 more

Conditions: Prader-Willi Syndrome
Interventions: Placebo, Guanfacine extended release (GXR); Other · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 6 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome
Interventions: AMX-883, Posaconazole; Drug
Lead sponsor: Amphista Therapeutics Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: New York, New York • Fairfax, Virginia

Conditions: Multiple Sclerosis
Interventions: Neuropsychological Feedback & Psychoeducation (Cognition), Psychoeducation (Health); Behavioral
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Peripheral T-Cell Lymphoma
Interventions: KW-0761; Biological
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 2 more

Conditions: Lung Cancer
Interventions: AZD2171, Etoposide, Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Sacramento, California • Denver, Colorado • Kansas City, Kansas + 1 more

Conditions: DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Interventions: AOC 1001, Placebo; Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more

Conditions: Hypertension
Interventions: Healthy Behavior Texts, No healthy behavior texts, BP Monitoring Daily Via Text Messaging, BP Monitoring Weekly Via Text Messaging, Physician appointment and transportation scheduling, No physician appointment and transportation scheduling; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Androgenetic Alopecia
Interventions: 5% Minoxidil Topical Foam, Vehicle Topical Foam; Drug
Lead sponsor: Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more

Conditions: Smoldering Multiple Myeloma
Interventions: Denosumab; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Microbiota
Interventions: OTC Eczema Moisturizer Regimen, Cosmetic Moisturizer Regimen; Drug · Other
Lead sponsor: Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.; Industry
Eligibility: 16 Years to 50 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Colorado Springs, Colorado • Richardson, Texas

Conditions: Thrombosis, Venous Thrombosis
Interventions: Alfimeprase; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Corvallis, Oregon

Conditions: Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia
Interventions: SPR001; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Orange, California • San Diego, California • Melbourne, Florida + 6 more

Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Refractory Anemia, Small Lymphocytic Lymphoma
Interventions: Cyclophosphamide, Cyclosporine, Double-Unit Umbilical Cord Blood Transplantation, Fludarabine, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Thiotepa; Drug · Procedure · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2024
U.S. locations: 3
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Atrial Fibrillation
Interventions: Aegis Sierra Ligation System; Device
Lead sponsor: Aegis Medical Innovations; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 4
States / cities: Santa Monica, California • Rochester, Minnesota • New York, New York + 1 more

Conditions: Sleep Initiation and Maintenance Disorders
Interventions: volinanserin (M100907), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 848 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Multiple Myeloma
Interventions: BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2; Combination Product
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Retinopathy
Interventions: BI 764524, Sham control of BI 764524; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more

Conditions: Glaucoma
Interventions: App; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib, sorafenib tosylate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Nodules
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.

A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

Intervention to Reduce Perceived Cognitive Impairment in Multiple Sclerosis

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

Reach Out: Emergency Department-Initiated Hypertension Behavioral Intervention Connecting Multiple Health Systems

Clinical Trial in Females for Female Pattern Hair Loss

Denosumab for Smoldering Multiple Myeloma

Clinical Trial to Assess the Effects of Topical Lotions on Changes in the Skin Microbiome and Associations With Itch

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters

Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Feasibility Study of a Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation

Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

An App-based Instructional Platform to Improve Eye Drop Recall

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

A Pilot Study of PET-CT in the Assessment of Pulmonary Nodules in Children With Malignant Solid Tumors